Respiratory syncytial virus hospitalization in children in northern Spain-Reference-Cited by-同舟云学术

Respiratory syncytial virus hospitalization in children in northern Spain

Published:2018-11-15 Issue:11 Volume:13 Page:e0206474
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Viguria Natividad^ORCID,Martínez-Baz Iván,Moreno-Galarraga Laura,Sierrasesúmaga Luis,Salcedo Blanca,Castilla Jesús^ORCID

Funder

This study has been partially funded by the Spanish Carlos III Institute of Health, the collaboration of the European Regional Development Fund

The Caixa Foundation

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Global, regional and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study;T Shi;Lancet,2017

2. Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance;JW Tang;Lancet Infect Dis,2017

3. Frequency of apnea and respiratory viruses in infants with bronchiolitis;S Ricart;Pediatr Infect Dis J,2014

4. Temporal trends of respiratory syncytial virus-associated hospital and ICU admissions across the United States;P Gupta;Pediatr Crit Care Med,2016

5. Respiratory syncytial virus-associated mortality in hospitalized infants and young children;CL Byington;Pediatrics,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain;BMC Infectious Diseases;2024-09-06

2. Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain;BMC Infectious Diseases;2024-08-05

3. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol;Human Vaccines & Immunotherapeutics;2024-05-13

4. Short‐ and mid‐term morbidity and primary‐care burden due to infant respiratory syncytial virus infection: A Spanish 6‐year population‐based longitudinal study;Pediatric Allergy and Immunology;2024-05

5. Epidemiology of Respiratory Syncytial Virus Hospitalizations in Poland: An Analysis from 2015 to 2023 Covering the Entire Polish Population of Children Aged under Five Years;Viruses;2024-04-29